Triethylamine 4-aryl-2-hydroxy-4-oxo-3-(2-oxo-3,4-dihydro - 2h-1,4-benzoxazine)-2-buta ene acid, exhibiting anti-inflammatory activity


(57) Abstract:

The invention relates to the field of organic chemistry, namely to new derivatives of amides heterylamine butenova acids that have anti-inflammatory activity. Describes triethylamine 4-aryl-2-hydroxy-4-oxo-3-(2-oxo-3,4-dihydro-2H-1,4-benzoxazine)-2-butenova acid of General formula

< / BR>
where R=R1- H (I);

R - H, R1- CH3(II);

R=R1- CH3(III);

R - H, R1- OCH3(IV)

exhibiting anti-inflammatory activity. The technical result - expanding Arsenal of tools have useful biological properties. table 2.

The invention relates to organic chemistry and synthesis of new chemical compounds - triethylamine 4-aryl-2-hydroxy-4-oxo-3-(2-oxo-3,4-dihydro-2H-1,4-benzoxazine)-2-butenova acid of General formula

< / BR>
where R= R1- H (I); R IS H, R1- CH3(II); R=R1- CH3(III); R IS H, R1- OCH3(IV)

possessing anti-inflammatory activity. This property suggests the possibility of using this series of compounds in medicine.

Available to the applicant sources known structural analog - pyridi the
has a weak antimicrobial activity, but does not have anti-inflammatory actions (I. C. Mashevsky, P. P. Makhmudov, A. Alexandrova, O. S. Kudinov, S. C. Koltsov, A. F. goleniów, A. N. Maslivets. The products of interaction of heterene[] 2,3-dihydro-2,3-pyrrolidino with aryl - and heteroarylboronic and their pharmacological activity. Chem. Pharm. Journe. Volume 34, 12, 2000, S. 13-16).

In medical practice known anti-inflammatory drug Voltaren, which is taken by the applicant as a benchmark to compare the anti-inflammatory activity of the claimed compounds. Practice standard for comparison of diclofenac sodium (ortofena, voltaren), which is a toxic compound showed the following side effects:

- medicinal hepatitis and cirrhosis of the liver - hepatotoxicity (Polunin I.e., Ter. Arch., 2,1988, S. 119-121);

- degenerative effect on the myocardium - cardiotoxicity (Stepanyuk, I., Stolyarchuk A. A. Pharmacol. and toxicol., 5, 1987, S. 89-93);

- nephrotoxic effect (Androsova S. O., Nikolaev A. Y. Rheumatology, 2, 1984, S. 54-57);

- gastrotoxicity (Subev R. D., Mashkovsky M. D., Schwartz, J., Pokryshkin C. I. Chem. forms. zhurn., 1, 1985, S. 33-39)

The objective of the invention is the synthesis of new p is SIRENIA Arsenal of means of influence on a living organism.

The method of obtaining compounds of General formula

< / BR>
where R= R1- H (I); R IS H, R1- CH3(II); R=R1- CH3(III); R IS H, R1- OCH3(IV)

lies in the interaction of 3-aroyl-1,2-dihydro-4H-pyrrolo-[5,1-C] [1,4] -benzoxazine-1,2,4-trions with 4-amino-1,2,4-triazole at room temperature when merging reagents in acetonitrile with the formation of triethylamine 4-aryl-2-hydroxy-4-oxo-3-(2-oxo-3,4-dihydro-2H-1,4-benzoxazine)-2-butenova acid (I-IV):

< / BR>
The invention is illustrated by the following examples.

Example 1. Triazine 4-phenyl-2-hydroxy-4-oxo-3-(2-oxo-3,4-dihydro-2H-1,4-benzoxazine)-2-butenova acid (I).

To a solution 3,19 g (10 mmol) of 3-benzoyl-2,4-dihydro-1H-pyrrolo[5,1-C] [1,4]benzoxazine-1,2,4-trione in 50 ml of acetonitrile is poured with stirring, a solution of 0.84 g (10 mmol) 4-amino-1,2,4-triazole in 30 ml of acetonitrile, precipitated pale yellow precipitate of compound I is filtered off and recrystallized from DMF.

The yield of compound I 3,57 (89%), So pl. 294-296oC.

Found, %: 59,47; N 2,70; N 17,43/ C20H11N5O5Calculated, %: 59,86; N Was 2.76; N 17,45.

Compounds II-IV are obtained similarly.

Characteristics of the synthesized sedimenation soluble in acetonitrile, acetone, toluene, soluble in DMSO, insoluble in water, hexane, benzene and giving a positive reaction (cherry staining) in the presence of the enol hydroxyl with an alcoholic solution of ferric chloride (III).

In the IR spectra of compounds I-IV are the bands of stretching vibrations lactone carbonyl benzoxazinones fragment WITH2=O in the field 1770-1780 cm-1, amide carbonyl WITH1=O in the field 1750-1760 cm-1, rolnego carbonyl in the field 1620's to 1640's cm-1and the absorption band of amide NH group in the field 3200-3250 cm-1and broad absorption band enol carbonyl - 3000-3160 cm-1.

In the PMR spectra of compounds I, III are the signals of aromatic protons in the region 6,80-of 7.90 M. D. , singlet amide NH groups in the area of 9.3 to 9.6 M. D., singlet 2 vinyl CH groups triazole fragment in the field 9,90-10,1 M. D. and two singlet methyl groups (compound III) when is 2.30 and 2.45 m D. the Signal of the proton enol group HE strongly broadened due to the intensive exchange with the solvent and is approximately in the region of 8 M. D.

Example 2. Pharmacological study of triethylamine 4-aryl-2-hydroxy-4-oxo-3-(2-oxo-3,4-dihydro-2H-1,4-benzoxazine)-2-butenova acid in the presence of the anti-Christ. sakh of both sexes weighing 180-220 g model carragenine edema [1]. Compounds were administered intraperitoneally one hour before subplanar injection of 0.1 ml of 1% aqueous solution carragenin. The effect was evaluated ecometrics at the 4th hour after the introduction of logogen by the percentage increase in the volume of inflamed feet to the original volume and was calculated the percentage inhibition of edema compared to control.

All compounds were administered intraperitoneally at a dose of 50 mg/kg in 2% starch mucus. Drug comparisons for anti-inflammatory activity served diclofenac sodium at a dose of 8 mg/kg [2]. Control group animals were injected equiano amount of 2% starch slime.

Each connection has been studied in 6 animals.

Acute toxicity of the compounds was determined by the method of C. B. Prozorovsky [3] on outbred white mice of both sexes weighing 18-22 g intraperitoneal route of administration.

Statistical processing of experimental data was performed using student's t-test [4]. The effect was considered significant at p<0,05.50more than 2000 mg/kg, which corresponds to the class practically non-toxic compounds according to the classification K. K. Sidorov [5].

All ISCA sodium (PL. 2).


1. Methodological guidance on experimental (preclinical) study of non-steroidal anti-inflammatory pharmacological substances. Approved by the Pharmacological Committee of the Ministry of health USSR (1982).

2. R. D. Shabaev, M. D. Mashkovsky, G. J. Schwarz, C. I. Pokryshkin, Chem. Pharm. journal.,19 (1), 33-39 (1985).

3. C. B. Prozorovskii, Pharmacol. and toxicol., 4, 497-502 (1978).

4. M. L. white, the Elements of a quantitative evaluation of the pharmacological effect, 2nd ed., Medical literature, Leningrad (1963).

5. K. K. Sidorov, " in proc.Toxicology of new industrial chemical substances (release 13), Moscow, Medicine, 47-51 (1973).

Triethylamine 4-aryl-2-hydroxy-4-oxo-3-(2-oxo-3,4-dihydro-2H-1,4-benzoxazine)-2-butenova acid of General formula

< / BR>
where R=R1-H(I);

R-H, R1-CH3(II);


R-H, R1-OCH3(IV)

exhibiting anti-inflammatory activity.


Same patents:

The invention relates to the derivatives of propanolamine formula (I) and their pharmaceutically acceptable salts, where R1and R2means phenyl, naphthyl, pyridyl, thienyl, pyrimidyl, thiazolyl, hinely, piperazinil, oxazolyl, which may be substituted with halogen, HE, NO2, NH2, COOH, etc., R3-R8mean hydrogen, hydroxyl, (C1-C8-alkoxy, NH2-THE OTHER9, -N(R9R10, R9-R10mean hydrogen or (C1-C8)alkyl, X is CH or N, Y represents CH or N, provided that the residues R1, R2X and Y are not simultaneously mean R1- phenyl, R2is phenyl, X is CH, Y is CH

The invention relates to new isoxazol derivative of formula 1, where D represents hydrogen; one of a and b is a group (1) -E-N= C(NR25R26)NR27R28; E represents a direct link or alkilinity group; R25and R26each represents, independently, hydrogen; C1-4-alkyl; -(CH2)n-CO2R32, n is an integer of 1-3, and R32represents hydrogen, C1-4-alkyl; -(CH2)m-CO2R35m is 2 or 3 and R35represents hydrogen, C1-4-alkyl; -(CH2)mHE, m defined above, or -(CH2)n-C(O)R36n is defined above and R3represents hydrogen, C1-4-alkyl; and t

The invention relates to substituted 1-phenylpyrazol-3-carboxamide formula (Ia) in which R1xis in position 4 or 5 and denotes the group-T-CONRaRbin which T represents a direct bond or (C1-C7-alkylen; NRaRbdenotes a group selected from (a), (b), (C); R5and R6denote, independently of one another, hydrogen, (C1-C6)-alkyl, (C3-C8)-alkenyl or R5and R6together with the nitrogen atom to which they are linked, represent a heterocycle selected from pyrrolidine, piperidine, research, piperazine, substituted in position 4 by Deputy R9; R7denotes hydrogen, (C1-C4)-alkyl or benzyl; R8denotes hydrogen, (C1-C4)-alkyl, or R7and R8together with the carbon atom to which they are attached, form a (C3-C5-cycloalkyl; R9denotes hydrogen, (C1-C4)-alkyl, benzyl or a group-X-NR'5R'6in which R'5and R'6represent, independently from each other, (C1-C6)-alkyl; R10denotes hydrogen, (C1-C4)-alkyl; s= 0-3; t=0-3, provided that (s+t) in the same group greater than or equal to 1; the divalent radicals a and E together with the atom is which in addition, may be substituted by one or more (C1-C4-alkilani; R2xand R3xdenote, independently of one another, hydrogen, (C1-C6)-alkyl, (C3-C8-cycloalkyl, (C3-C8-cyclooctylmethyl provided that R2xand R3xdo not simultaneously denote hydrogen or R2xand R3xtogether form tetramethylene group; and their pharmaceutically acceptable salts

The invention relates to compounds of the formula I

< / BR>
in which R1denotes-C(=NH)-NH2which may be substituted once by a group-COA, -CO-[C(R6)2]n-Ar, -COOA, -HE or normal aminosidine group

< / BR>
R2denotes H, A, OR6N(R6)2, NO2CN, Hal, NHCOA, NHCOAr, NHSO2A, NHSО2Ar, COOR6, SOPS(R6)2, CONHAr, COR6, COAr, S(O)nA or S(O)nAr,

R3means And, cycloalkyl, - [C(R6)2]nAr, - [C(R6)2]n-O-Ar, -[C(R6)2]nHet or-C(R6)2=C(R6)2-Ar,

R6denotes H, a or benzyl,

X is absent or represents-CO-, -C(R6)2-, -C(R6)2-C(R6)2-, -C(R6)2-CO-, -C(R6)2-C(R6)2-CO-, -C(R6)= C(R6)-CO-, NR6CO-, -N{[CR6)2]n-COOR6} -CO - or-C(COOR6R6-C(R6)2-CO-,

Y represents-C(R6)2-, -SO2-, -CO-, -COO - or-CONR6-,

And denotes alkyl with 1-20 C-atoms, where one or two CH2-groups can be replaced by O - or S-atom or single, two - or three-fold substituted by the group And, Ah', OR6N(R6)2, NO2CN, Hal, NHCOA, NHCOAr', NHSO2A, NHSО2Ar', COOR6, CON(R6)2, CONHAr', COR6, COAr', S(O)nA or S(O)nAr is phenyl or naphthyl,

AG' refers to unsubstituted or one-, two - or three-fold substituted by a group A, OR6N(R6)2, NO2CN, Hal, NHCOA, COOR6, SOPS(R6)2, COR6or S(0)nA phenyl or naphthyl,

Het denotes a single or dual core unsubstituted or one - or multi-substituted by a group of Hal, A, Ar', COOR6, CN, N(R6)2, NO2, Ar-CONH-CH2and/or carbonyl oxygen saturated or unsaturated heterocyclic ring system containing one, two, three or four identical or different heteroatoms, such as nitrogen, oxygen or sulphur,

Hal denotes F, C1, Br or J,

n denotes 0, 1 or 2,

and their salts

The invention relates to new derivatives of kalaidjieva, fungicides, method of combating fungal diseases of crops and intermediate compounds for obtaining

The invention relates to new derivatives of piperidine-ketocarboxylic acids of the formula (I), where R1- COR4or SO2R4, R4means of alkenyl, substituted phenyl or pyridine, naphthyl, honokalani, chinoline, benzothiophene, dihydroxyphenyl or pyridyl, substituted with allmineral, R2- C1-C6-alkyl which can be substituted by phenyl or pyridium, R3group-OR6or other6where R6means hydrogen, C1-C6-alkyl, which may be a phenyl, pyridine or morpholinium, their tautomeric and isomeric forms, and salts

The invention relates to new derivatives of benzoxazinone General formula (I), where R1means N or carboxyethyl, R2represents hydrogen or alkyl, and R3is a different derivatively of amino acids, dipeptides and hydrazones acid groups, respectively, their conjugates with active substances, such as residues from a number of penicillin
The invention relates to pharmaceutical industry

The invention relates to the field of medicine and relates to farbkomposition for inhibition of metalloproteinases containing sulfonated amino acid derivatives, and new sulfonated amino acid derivatives

The invention relates to the derivatives of pyrrolidine formula I

< / BR>
where R1- H, C1-C6alkyl; phenyl, possibly substituted; biphenyl, possibly substituted; 1H, 5H - pyrido [3,2,1-ij] chinolin; phenyl WITH1-C6alkyl, optionally substituted; biphenyl WITH1-C6alkyl, optionally substituted; biphenylcarboxylic; terphenyl; naphthyl, optionally substituted; Z denotes-S-, -O-, -och2-, -N(R16), where R16- H, C1-C6alkyl, C3-C8cycloalkyl1-C6alkyl, panels1-C6alkyl, a chemical bond; X1means-CO-, -(CH2)r-CO-N(R17), where R17means H, C1-C6alkyl (where r = 0 or 1), -CH2NHSO2-, -(CH2)s-N (R18)-CO- (where R18- N, s=1-3), - CH2NHCОСН2O-, -CH2N (R19Of PINES = CH- (where R19- H, -CH2OCH2-, -CH2-N (R20)-CH2- (where R20- H, C1-C6alkyl, C1-C6alkylsulphonyl, phenylcarbinol)1-C5alkylen,2-C4albaniles, a chemical bond; X2- phenylene, optionally substituted hydroxy, theoffender, purandar, piperidinyl,< / BR>
< / BR>
< / BR>
R2and R3each - H; and R4- phenyl, possibly substituted with halogen; R5- phenyl, possibly substituted; a cycle of G is phenyl,3-C7cycloalkyl, pyridyl, thienyl; loop J is phenyl; L is phenyl; p=0-2;----- means the presence or absence of chemical bonding;displays a CIS - or TRANS-configuration D relative to E; provided that X1means-CH2NHCО-, X2means 1,4-phenylene and X3means a chemical bond or a C1-C5alkylen, when the carbon atom bound CD and adjacent carbon atom in the cycle are connected by a simple relation and V1does not mean a chemical bond, when X1means-CH2O-; and pharmaceutically acceptable salt or hydrate of the compound

The invention relates to novel 2,4-dioxo-5-arylidene-1,3-pyrimidines of General formula I, where R is independently selected from the group: H, HE, lowest alkoxyl, halogen, nitro, di(lower)alkylamino, n = 1-3, or two adjacent R along the benzene ring to which they are attached, when n = 2, 4 form a benzo, and dibenzo when n = 2 form a 3,4-dioxolane ring

The invention relates to medicine, and is concerned medicines, which have immunomodulatory effects that are used for non-injection use for the prevention and treatment of diseases caused by impaired immune functions

The invention relates to new substituted the amino compounds of the formula I, their pharmaceutically acceptable salts and method of production thereof

The invention relates to medicine and relates to pharmaceutical compositions for oral administration, which produces the desired therapeutic response, in tablets, drops or other molded form, which includes potassium, sodium or Tris salt oxaprozin, and tablet, caplet or other molded form of pharmaceutical compositions is usually dissolved by approximately 75% in environments phosphate buffer for about 30 min
The invention relates to medicine and relates to a means and method for the treatment of infectious-inflammatory diseases
The invention relates to medicine, in particular to pharmaceutical preparations, which represents an antimicrobial agent